Our Impact

Our Research

research mission

progressive research and big data

Our mission is to advance treatment discovery at a pace which helps our patients today.
Until now, big data has largely been applied to the commercial world, predicting human interactions and behaviors. Imagine if the same principles of big data in the commercial world applied to the medical world — driving research hypotheses, treatment protocols, and medical outcomes. This very idea powers the TPIRC clinical care and research model. TPIRC truly is where big data meets big medicine.

Heading our research facility is Dr. Marsteller, a molecular biologist with an emphasis on immunology and pulmonology. He has four main areas of interest. First, he studies bronchopulmonary dysplasia and noninvasive ventilation strategies and their effects and lung development at the structural and genetic level.

Second, he works to identify patients with cystic fibrosis that are at high risk for significant decline in lung function which will enable address of potential therapeutic remission, modalities, environmental exposures, and behavioral variants that may improve outcomes in these patients. Third, Dr. Marsteller is focused on the immune system, specifically food allergies and how the gut microbiota stimulates the immune system and how these interactions impact the development of food allergies. Fourth, he has spearheaded the launch of the TPIRC Biobank which allows characterizing all of these different aspects by studying the immune response of our patients with the goal of helping our patients today!

Research Areas


Clinical Precision Medicine Research

Precision medicine advances science and medical treatment in a complex yet effective approach of the "N=1". The N of any study is the number of patients. With more than 6,000 patients treated for severe food allergic disease, the N of our Institute exceeds that of many worldwide. The beauty of precision medicine is we are able to take thousands of individuals and utilize each of their cases to unmask millions of data points in their system of "1". TPIRC focuses on the development of cutting edge, individualized treatment protocols for orphan diseases utilizing comprehensive diagnostic tools, and patient-driven research.
This unique approach is advocated by the National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), and leading research centers across the globe. While complex and difficult in its statistical analysis, this class of research offers the greatest hope in analyzing the "personalized" medicine.

Translational science Research

Translational research is classically referred to as "from bench to bedside.” Each of our patients undergoes 300 or more diagnostic biomarker tests. This data is reflective of their immune system from the bone marrow to the gastrointestinal tract. We utilize this data to extrapolate novel findings and study them in patients with orphan diseases.
This approach aids in creating the best diagnostics possible. Additionally, the long-term follow-up of patients involving the standardization of biomarkers will be critical to the lifelong treatment outcomes of food allergy patients.

Labroratory Research

TPIRC is home to basic science research focused on orphan diseases. Research at the level of DNA, RNA, immune cells, and more are critical to the development of newer treatments for our patients. We are particularly focused on the identification of new biomarkers that can predict and reflect short-term molecular changes and long-term impact changes toward immune system tolerance. Dr. Marsteller is using his skills as a molecular biologist to conduct research on pulmonary diseases including neonatal chronic lung disease known as Bronchopulmonary Dysplasia (BPD) and other related pulmonary diseases in children.
He will be working in collaboration with a number of other faculty members, including Dr. Parviz Minoo, Hastings Professor of Pediatrics, and Dr. Changgong Li, Associate professor of Pediatrics in the Division of Neonatology at USC. Neonatal chronic lung disease has been a major challenge in Pediatrics and the incidence of this morbid and sometimes lethal disease has remained constant over the last four decades. The studies designed and conducted by Dr. Marsteller are directed at overcoming the barriers to effective treatment of BPD by expanding our understanding of its etiology. Our hope is to be able to contribute in a major way towards the eradication of neonatal chronic lung disease.

tpirc research mission

TPIRC is equipped with a state-of-the-art research facility where discovery is driven by the study of more than 1 trillion data points.
With each case that we treat, we continue to grow our data sets at an exponential rate. This form of data collection and analysis opens the door for truly patient-driven research derived from real-world, clinical data and outcomes rather than laboratory hypotheses. This collection of shared information offers the greatest hope to truly advance treatment protocols for some of the most complex conditions.

This application of this model in both our clinic and our research center is what will enable us to fulfill our two-fold mission - to advance treatment discovery at a pace which helps our patients today, while building scalable models of success to accelerate the rate of research discovery for all diseases.

Core Facilities

Current Studies

Cystic Fibrosis: Neutrophil
Population Characterization

Dysplasia CPAP Model

BPD Macrophage

SARS-CoV-2 Asymptomatic
Pediatric Cohort

Anxiety and Food Allergy

Almond Prevalence

Protein Characterization

Walnut Prevalence

Cesarean Section and
Food Allergies

Peer Reviewed Publications

Click to download